

JAN 04 2005

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON & BIRD LLP

3201 Beechleaf Court, Suite 600
Raleigh, NC 27604-1062
919-862-2200
Fax: 919-862-2260

TELECOPY**PLEASE DELIVER AS SOON AS POSSIBLE****Date:**

January 4, 2005

Recipient:

Mail Stop Amendment

Company:

U.S. Patent & Trademark Office

Fax Number:

703-872-9306

Voice Number:**Sender:**

C. Allen Black

Message:

Please file the attached Amendment in the following application:

Appl. No.: 10/674,750

Confirmation No.: 4229

Applicant(s): Vodyanoy *et al.*

Filed: September 30, 2003

Art Unit: 1653

Examiner: Robert B. Mondesi

Title: METHOD OF ISOLATION AND SELF-ASSEMBLY OF SMALL PROTEIN
PARTICLES FROM BLOOD AND OTHER BIOLOGICAL MATERIALS

Number of Pages: (including cover page)

17

IF NOT RECEIVED PROPERLY, PLEASE NOTIFY US IMMEDIATELY AT Karyn Grimm.

USER CODE:	BLACA	REQUESTED BY:	Karyn Grimm
CLIENT/MATTER:	035721 / 267665	OPERATOR:	

JAN 04 2005

Attorney's Docket No. 035721/267665

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/674,750 Confirmation No.: 4229
Applicant(s): Vodyanoy *et al.*
Filed: September 30, 2003
Art Unit: 1653
Examiner: Robert B. Mondesi
Title: METHOD OF ISOLATION AND SELF-ASSEMBLY OF SMALL PROTEIN
PARTICLES FROM BLOOD AND OTHER BIOLOGICAL MATERIALS

Docket No.: 035721/267665
Customer No.: 00826

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**AMENDMENT
37 C.F.R. §1.121**

Sir:

In response to the Office Action dated August 10, 2004, please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims beginning on page 8 of this paper.

Remarks/Arguments begin on page 12 of this paper.

RTA01/2160570v1